- Valuation
- ₹6,788 Cr

About Hikal
Hikal is a publicly listed company based in Mumbai (India) founded in 1988 by Jai Hiremath. APIs and intermediates are produced via custom synthesis and research. The company has 2,645 employees. Its website hikal.com draws about 10 thousand monthly visits. Its Indian entity Hikal Limited reported revenue of βΉ1,725 Cr. Hikal offers products and services including Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed competitors have raised funding.
Company details
Hikal was founded in 1988 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical and chemical sectors, where contract research, custom synthesis, and manufacturing of active pharmaceutical ingredients (APIs) and intermediates are conducted. Services extend to supplying ingredients for medicine production and providing research and development support for life sciences and biotechnology firms developing new products.
Recognitions & Rankings of Hikal
- Market Cap₹2,738 Cr
HIKAL · NSE
- Share Price₹220.76
-0.59% today
- Revenue₹1,713 Cr
FY 2025-26 · -7.9% YoY
- EBITDA₹135 Cr
Margin 7.9%
- Net Profit₹27.20 Cr
FY 2025-26 · -69.8% YoY
- P/E (TTM)38.6x
P/B 2.3x
- ROE2.2%
ROCE 3.4%
- Debt / Equity0.59
Interest cover -217.9x
- Latest Funding Round$50M (USD), Post-IPO
Nov 2021
- Investors
- Employee Count2,645
Associated legal entities of Hikal
Hikal is associated with 2 registered companies on The Company Check; the primary company is Hikal Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Hikal Limited Listed CIN L24200MH1988PTC048028 | Active | 08 Jul 1988 | Mumbai, Maharashtra | ₹1,725 Cr | 2,192 | 11 | View details |
| Hikal Pharmaceuticals Limited CIN U26921MH1985PTC171427 | Amalgamated | 23 Sep 1985 | Navi Mumbai, Maharashtra | $216.0M | 3 | View details |
Products & Services of Hikal
Hikal offers a comprehensive portfolio of products and services, including Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products.
Offers custom manufacturing for pharmaceutical and chemical products
Provides active pharmaceutical ingredients for various applications
Delivers intermediates and solutions for animal health sector
Funding Insights of Hikal
- Total Rounds 3
- Last Round Post-IPO β $50M
- First Round $9.09M
(Jun 2008)
- Investors Count 1
All 3 funding rounds of Hikal with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Hikal
Hikal has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include International Finance Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
IFC is focused on private sector development in emerging markets. | 1956 | ifc.org |
Investor details for Hikal
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Hikal Limited (Hikal)
Hikal Limited is the primary company behind Hikal. The boards of the 2 registered companies of Hikal currently have 12 directors; the longest-serving is Sameer Jai Hiremath, appointed in 1999. 14 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sameer Jai Hiremath DIN 00062129 | Managing Director | 26 May 1999 | 27 yrs 5 mo | Hikal Limited |
| Sham Vinayak Wahalekar DIN 00058031 | Director | 18 Jun 2004 | 22 yrs 5 mo | Hikal Pharmaceuticals Limited |
| Shivakumar Kheny DIN 01487360 | Director | 10 Jul 2004 | 22 yrs 4 mo | Hikal Pharmaceuticals Limited |
| Ravindra Murgendra Khadabadi DIN 00108205 | Director | 22 Dec 2005 | 20 yrs 10 mo | Hikal Pharmaceuticals Limited |
| Amit Babasaheb Kalyani DIN 00089430 | Director | 09 Feb 2012 | 14 yrs 9 mo | Hikal Limited |
| Shivani Bhasin Sachdeva DIN 00590500 | Director | 01 Aug 2019 | 7 yrs 3 mo | Hikal Limited |
| Shrikrishna Kiran Adivarekar DIN 06928271 | Director | 22 Dec 2021 | 4 yrs 10 mo | Hikal Limited |
| Ramachandra Kaundinya Vinnakota DIN 00043067 | Director | 01 Oct 2023 | 3 yrs 1 mo | Hikal Limited |
| Ravi Brijmohan Kapoor DIN 01761752 | Director | 11 Jan 2024 | 2 yrs 10 mo | Hikal Limited |
| Ranjana Shivanand Salgaocar DIN 00120120 | Director | 23 Mar 2024 | 2 yrs 7 mo | Hikal Limited |
| Suresh Sarangan DIN 10562713 | Whole-time director | 01 Apr 2024 | 2 yrs 7 mo | Hikal Limited |
| Sandip Ashwinbhai Parikh DIN 00030990 | Director | 27 May 2026 | 5 mo | Hikal Limited |
People of Hikal
37 people are tracked at Hikal (15 in leadership, 11 in board & advisors, 11 in team); the tracked headcount is 2,645.
| Name | Role | Group |
|---|---|---|
| Founder | Leadership | |
Vidyanand Shetty | Head - Business Hr, Pharma Division, Bangalore | Leadership |
Vimal Kulshrestha | President, Crop Protection | Leadership |
Raghavendar Rao Morthala | Sr. Vice President And Head – CDMO R&t Pharma & Animal Health BU | Leadership |
Nalin Diwan | General Manager (cdmo Business) | Leadership |
Abhijit Chandode | Operation Head | Leadership |
Vinay Baliga | Senior Vice President Finance | Leadership |
Manoj Mehrotra | President, Pharmaceuticals | Leadership |
Kuldeep Jain | CFO | Leadership |
Ratish Jha | President, Human Resources | Leadership |
Kailas Bharambe | Head Operations, Animal Health, Panoli | Leadership |
Anish Swadi | Senior President, Animal Health & Business Transformation | Leadership |
Anup Aurangabadkar | General Manager - HR & Admin, Research & Technology Centre | Leadership |
Kinjal Panchal | Deputy General Manager Human Resources | Leadership |
Sanchit Sinha | Senior General Manager & Head Corporate HR | Leadership |
Prakash Mehta | Director | Board & advisors |
Sugandha Hiremath | Director | Board & advisors |
Axel Kleemann | Scientific Advisor | Board & advisors |
Baba Kalyani | Director | Board & advisors |
| Director | Board & advisors |
17 more people are available in the full profile.
Complete people profiles for Hikal
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Hikal
Hikal is a publicly listed company on the NSE with ticker symbol HIKAL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Feb 2001
- Listed onNSE: HIKAL
- Listed entityHikal Limited
- Exchange sectorHealth technology
- ISININE475B01022
- Share price₹218.68 (+2.61% on the day) · 2026-10-14
- Market capitalisation₹2,629 Cr
- Price to earnings276.0
- EPS (diluted, trailing year)₹-2.74
- Dividend yield0.28%
- Volume (last session)267,708
Financials of Hikal
Exchange-reported figures of Hikal Limited, the listed company behind Hikal (NSE: HIKAL).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,713 | 1,860 | 1,785 | 2,023 | 1,943 | 1,720 | 1,507 |
| Revenue growth | -7.9% | +4.2% | -11.8% | +4.1% | +12.9% | +14.1% | - |
| EBITDA | 135 | 328 | 267 | 257 | 341 | 323 | 258 |
| EBITDA margin | +7.9% | +17.7% | +15.0% | +12.7% | +17.5% | +18.8% | +17.1% |
| Profit before tax | (78.30) | 124 | 95.50 | 105 | 219 | 206 | 127 |
| Net profit | 27.20 | 90.17 | 69.23 | 77.92 | 160 | 133 | 94.79 |
| Net profit margin | +1.6% | +4.9% | +3.9% | +3.9% | +8.3% | +7.7% | +6.3% |
| EPS (βΉ) | (3.95) | 7.35 | 5.64 | 6.36 | 13.02 | 10.80 | 6.85 |
| Balance sheet | |||||||
| Total assets | 1,990 | 2,102 | 2,093 | 1,950 | 1,796 | 1,566 | 1,481 |
| Net worth | 1,199 | 1,262 | 1,188 | 1,133 | 1,068 | 933 | 816 |
| Total debt | 684 | 765 | 818 | 748 | 675 | 610 | 646 |
| Cash & bank | 13.80 | 18.00 | 20.88 | 59.55 | 49.09 | 36.81 | 63.57 |
| Net working capital | 513 | 601 | 602 | 536 | 573 | 569 | 520 |
| Cash flow | |||||||
| Cash from operations | 302 | 280 | 187 | 315 | 294 | 229 | 285 |
| Cash from investing | (145) | (136) | (174) | (292) | (284) | (156) | (164) |
| Cash from financing | (160) | (144) | (27.00) | (7.68) | (5.56) | (96.87) | (101) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 434 | 403 | 519 | 494 | 318 | 380 | 552 | 448 |
| Revenue growth (YoY) | +36.3% | +5.9% | -6.0% | +10.4% | -29.7% | -6.5% | - | - |
| Other income | 1.70 | 10.70 | 6.60 | 2.80 | 1.90 | 1.00 | 0.50 | 3.60 |
| EBITDA | 44.90 | 37.00 | 58.30 | 44.70 | 7.20 | 25.10 | 123 | 72.10 |
| EBITDA margin | +10.4% | +9.3% | +11.3% | +9.1% | +2.3% | +6.8% | +22.4% | +16.4% |
| Depreciation | 41.70 | 42.70 | 42.00 | 41.20 | 41.20 | 39.40 | 37.70 | 33.20 |
| Interest | 13.40 | 14.90 | 14.60 | 15.50 | 14.90 | 17.10 | 17.90 | 18.70 |
| Profit before tax | (8.50) | (9.90) | 8.30 | (9.20) | (47.00) | (30.40) | 68.30 | 23.80 |
| Tax | (2.40) | (2.50) | (6.10) | (3.30) | (12.10) | (8.00) | 18.10 | 6.60 |
| Net profit | (6.10) | (7.40) | 14.40 | (5.90) | (34.90) | (22.40) | 50.20 | 17.20 |
| EPS (βΉ) | (0.49) | (0.60) | 1.17 | (0.48) | (2.83) | (1.82) | 4.07 | 1.39 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,713 | 1,860 | 1,785 | 2,023 | 1,943 | 1,720 | 1,507 |
| Revenue growth | -7.9% | +4.2% | -11.8% | +4.1% | +12.9% | +14.1% | - |
| EBITDA | 135 | 328 | 267 | 257 | 341 | 323 | 258 |
| EBITDA margin | +7.9% | +17.7% | +15.0% | +12.7% | +17.5% | +18.8% | +17.1% |
| Profit before tax | (78.20) | 124 | 95.40 | 105 | 219 | 206 | 127 |
| Net profit | 27.30 | 90.27 | 69.08 | 77.92 | 160 | 133 | 94.80 |
| Net profit margin | +1.6% | +4.9% | +3.9% | +3.9% | +8.3% | +7.7% | +6.3% |
| EPS (βΉ) | (3.94) | 7.36 | 5.63 | 6.36 | 13.02 | 10.80 | 6.85 |
| Balance sheet | |||||||
| Total assets | 1,990 | 2,102 | 2,092 | 1,950 | 1,796 | 1,566 | 1,481 |
| Net worth | 1,199 | 1,262 | 1,188 | 1,133 | 1,068 | 933 | 817 |
| Total debt | 684 | 765 | 818 | 748 | 675 | 610 | 646 |
| Cash & bank | 13.80 | 17.90 | 20.80 | 59.53 | 49.09 | 36.81 | 63.57 |
| Net working capital | 513 | 602 | 602 | 536 | 573 | 569 | 520 |
| Cash flow | |||||||
| Cash from operations | 302 | 280 | 187 | 315 | 294 | 229 | 285 |
| Cash from investing | (145) | (136) | (174) | (292) | (284) | (156) | (164) |
| Cash from financing | (160) | (144) | (27.00) | (7.68) | (5.56) | (96.87) | (101) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 434 | 403 | 519 | 494 | 318 | 380 | 552 | 448 |
| Revenue growth (YoY) | +36.3% | +5.9% | -6.0% | +10.4% | -29.7% | -6.5% | - | - |
| Other income | 1.70 | 10.70 | 6.60 | 2.80 | 1.90 | 1.00 | 0.50 | 3.60 |
| Total expenses | 389 | 366 | 461 | 450 | 311 | 356 | 429 | 376 |
| EBITDA | 44.80 | 36.90 | 58.50 | 44.70 | 7.40 | 24.80 | 124 | 72.20 |
| EBITDA margin | +10.4% | +9.2% | +11.3% | +9.1% | +2.3% | +6.7% | +22.5% | +16.5% |
| Depreciation | 41.70 | 42.70 | 42.00 | 41.20 | 41.20 | 39.40 | 37.70 | 33.20 |
| Interest | 13.40 | 14.90 | 14.60 | 15.50 | 14.90 | 17.10 | 17.90 | 18.70 |
| Profit before tax | (8.60) | (10.00) | 8.50 | (9.20) | (46.80) | (30.70) | 68.40 | 23.90 |
| Tax | (2.40) | (2.50) | (6.10) | (3.30) | (12.10) | (8.00) | 18.10 | 6.60 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 434 | 403 | 519 | 494 | 318 | 380 | 552 | 448 |
| Revenue growth (YoY) | +36.3% | +5.9% | -6.0% | +10.4% | -29.7% | -6.5% | - | - |
| Other income | 1.70 | 10.70 | 6.60 | 2.80 | 1.90 | 1.00 | 0.50 | 3.60 |
| EBITDA | 44.90 | 37.00 | 58.30 | 44.70 | 7.20 | 25.10 | 123 | 72.10 |
| EBITDA margin | +10.4% | +9.3% | +11.3% | +9.1% | +2.3% | +6.8% | +22.4% | +16.4% |
| Depreciation | 41.70 | 42.70 | 42.00 | 41.20 | 41.20 | 39.40 | 37.70 | 33.20 |
| Interest | 13.40 | 14.90 | 14.60 | 15.50 | 14.90 | 17.10 | 17.90 | 18.70 |
| Profit before tax | (8.50) | (9.90) | 8.30 | (9.20) | (47.00) | (30.40) | 68.30 | 23.80 |
| Tax | (2.40) | (2.50) | (6.10) | (3.30) | (12.10) | (8.00) | 18.10 | 6.60 |
| Net profit | (6.10) | (7.40) | 14.40 | (5.90) | (34.90) | (22.40) | 50.20 | 17.20 |
| EPS (βΉ) | (0.49) | (0.60) | 1.17 | (0.48) | (2.83) | (1.82) | 4.07 | 1.39 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,713 | 1,860 | 1,785 | 2,023 | 1,943 | 1,720 | 1,507 |
| Revenue growth | -7.9% | +4.2% | -11.8% | +4.1% | +12.9% | +14.1% | - |
| Other income | 12.30 | 5.00 | 2.45 | 5.41 | 4.89 | 4.98 | 3.70 |
| Total expenses | 1,577 | 1,531 | 1,518 | 1,766 | 1,602 | 1,398 | 1,250 |
| Employee cost | 270 | 247 | 247 | 222 | 203 | 164 | 157 |
| EBITDA | 135 | 328 | 267 | 257 | 341 | 323 | 258 |
| EBITDA margin | +7.9% | +17.7% | +15.0% | +12.7% | +17.5% | +18.8% | +17.1% |
| Depreciation | 164 | 134 | 118 | 109 | 95.67 | 85.25 | 82.46 |
| Interest | 62.10 | 75.20 | 56.37 | 48.10 | 31.22 | 36.20 | 52.42 |
| Profit before tax | (78.30) | 124 | 95.50 | 105 | 219 | 206 | 127 |
| Tax | (29.50) | 33.00 | 25.90 | 26.99 | 58.06 | 73.28 | 42.14 |
| Net profit | 27.20 | 90.17 | 69.23 | 77.92 | 160 | 133 | 94.79 |
| Net profit margin | +1.6% | +4.9% | +3.9% | +3.9% | +8.3% | +7.7% | +6.3% |
| EPS (βΉ) | (3.95) | 7.35 | 5.64 | 6.36 | 13.02 | 10.80 | 6.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.70 | 24.70 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 |
| Reserves & surplus | 1,174 | 1,238 | 1,163 | 1,109 | 1,043 | 909 | 792 |
| Shareholders' funds (net worth) | 1,199 | 1,262 | 1,188 | 1,133 | 1,068 | 933 | 816 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 552 | 630 | 711 | 663 | 559 | 514 | 551 |
| Unsecured loans | 132 | 134 | 106 | 84.99 | 116 | 95.94 | 94.92 |
| Total debt | 684 | 765 | 818 | 748 | 675 | 610 | 646 |
| Total liabilities | 1,990 | 2,102 | 2,093 | 1,950 | 1,796 | 1,566 | 1,481 |
| Assets | |||||||
| Gross block | 2,404 | 2,225 | 1,802 | 1,564 | 1,388 | 1,128 | 1,065 |
| Net block | 1,333 | 1,364 | 1,071 | 948 | 879 | 713 | 735 |
| Capital work in progress | 94.50 | 121 | 414 | 412 | 295 | 254 | 161 |
| Investments | 9.50 | 9.50 | 5.35 | 5.30 | 10.91 | 0.61 | 0.68 |
| Inventories | 358 | 334 | 304 | 317 | 329 | 267 | 312 |
| Sundry debtors | 442 | 522 | 550 | 442 | 438 | 486 | 340 |
| Cash & bank balances | 13.80 | 18.00 | 20.88 | 59.55 | 49.09 | 36.81 | 63.57 |
| Loans & advances | 70.60 | 120 | 91.67 | 121 | 138 | 89.56 | 58.29 |
| Total current assets | 884 | 995 | 967 | 939 | 954 | 879 | 775 |
| Total current liabilities | 371 | 394 | 365 | 403 | 381 | 310 | 255 |
| Net working capital | 513 | 601 | 602 | 536 | 573 | 569 | 520 |
| Total assets | 1,990 | 2,102 | 2,093 | 1,950 | 1,796 | 1,566 | 1,481 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 13.00 | 12.70 | 26.73 | 11.44 | 7.64 | 31.68 | 11.41 |
| Net cash from operating activities | 302 | 280 | 187 | 315 | 294 | 229 | 285 |
| Net cash from investing activities | (145) | (136) | (174) | (292) | (284) | (156) | (164) |
| Net cash from financing activities | (160) | (144) | (27.00) | (7.68) | (5.56) | (96.87) | (101) |
| Net change in cash | (3.40) | 0.30 | (14.03) | 15.29 | 3.80 | (24.05) | 20.27 |
| Closing cash | 13.80 | 18.00 | 20.88 | 59.55 | 49.09 | 36.81 | 63.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -7.9% | +4.2% | -11.8% | +4.1% | +12.9% | +14.1% | - |
| EBITDA growth | -58.8% | +23.0% | +3.9% | -24.5% | +5.5% | +25.3% | - |
| PBT growth | - | +29.6% | -9.4% | -51.8% | +5.9% | +63.1% | -15.1% |
| Net income growth | -69.8% | +30.3% | -11.2% | -51.4% | +20.5% | +40.4% | - |
| Revenue CAGR (3Y) | -5.4% | -1.4% | +1.2% | +10.3% | +6.9% | +9.9% | +14.1% |
| EBITDA CAGR (3Y) | -19.3% | -1.2% | -6.1% | -0.1% | +4.5% | +10.1% | +9.9% |
| Profitability & leverage | |||||||
| Net income margin | -2.9% | +4.9% | +3.9% | +3.9% | +8.3% | +7.7% | +5.6% |
| Return on capital employed | +3.4% | +9.5% | +7.5% | +8.2% | +14.9% | +15.9% | +13.4% |
| Return on net worth | +2.2% | +7.4% | +6.0% | +7.1% | +16.0% | +15.2% | +12.1% |
| Debt / equity | 0.59 | 0.65 | 0.67 | 0.65 | 0.64 | 0.72 | 0.83 |
| Long-term debt / equity | 0.30 | 0.32 | 0.39 | 0.35 | 0.27 | 0.32 | 0.38 |
| Interest cover | -217.89 | 38.76 | 37.73 | 32.49 | 12.75 | 15.23 | 29.90 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.74 | 0.92 | 1.06 | 1.37 | 1.54 | 1.57 | 1.49 |
| Inventory turnover | 4.95 | 5.83 | 5.75 | 6.27 | 6.52 | 5.94 | 4.45 |
| Debtors turnover | 3.55 | 3.47 | 3.60 | 4.60 | 4.21 | 4.17 | 4.37 |
| EPS (βΉ) | (3.95) | 7.35 | 5.64 | 6.36 | 13.02 | 10.80 | 6.85 |
| Dividend per share (βΉ) | 0.60 | 1.40 | 1.20 | 1.20 | 1.60 | 2.00 | 1.20 |
| Book value per share (βΉ) | 97.07 | 102.21 | 96.32 | 91.93 | 86.62 | 75.70 | 66.22 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 434 | 403 | 519 | 494 | 318 | 380 | 552 | 448 |
| Revenue growth (YoY) | +36.3% | +5.9% | -6.0% | +10.4% | -29.7% | -6.5% | - | - |
| Other income | 1.70 | 10.70 | 6.60 | 2.80 | 1.90 | 1.00 | 0.50 | 3.60 |
| Total expenses | 389 | 366 | 461 | 450 | 311 | 356 | 429 | 376 |
| EBITDA | 44.80 | 36.90 | 58.50 | 44.70 | 7.40 | 24.80 | 124 | 72.20 |
| EBITDA margin | +10.4% | +9.2% | +11.3% | +9.1% | +2.3% | +6.7% | +22.5% | +16.5% |
| Depreciation | 41.70 | 42.70 | 42.00 | 41.20 | 41.20 | 39.40 | 37.70 | 33.20 |
| Interest | 13.40 | 14.90 | 14.60 | 15.50 | 14.90 | 17.10 | 17.90 | 18.70 |
| Profit before tax | (8.60) | (10.00) | 8.50 | (9.20) | (46.80) | (30.70) | 68.40 | 23.90 |
| Tax | (2.40) | (2.50) | (6.10) | (3.30) | (12.10) | (8.00) | 18.10 | 6.60 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,713 | 1,860 | 1,785 | 2,023 | 1,943 | 1,720 | 1,507 |
| Revenue growth | -7.9% | +4.2% | -11.8% | +4.1% | +12.9% | +14.1% | - |
| Other income | 12.30 | 5.00 | 2.50 | 5.41 | 4.89 | 4.98 | 3.70 |
| Total expenses | 1,577 | 1,531 | 1,518 | 1,766 | 1,602 | 1,398 | 1,250 |
| Employee cost | 266 | 242 | 244 | 220 | 201 | 164 | 157 |
| EBITDA | 135 | 328 | 267 | 257 | 341 | 323 | 258 |
| EBITDA margin | +7.9% | +17.7% | +15.0% | +12.7% | +17.5% | +18.8% | +17.1% |
| Depreciation | 164 | 134 | 118 | 109 | 95.67 | 85.25 | 82.46 |
| Interest | 62.10 | 75.20 | 56.40 | 48.10 | 31.22 | 36.20 | 52.42 |
| Profit before tax | (78.20) | 124 | 95.40 | 105 | 219 | 206 | 127 |
| Tax | (29.50) | 33.00 | 25.90 | 26.99 | 58.06 | 73.28 | 42.14 |
| Net profit | 27.30 | 90.27 | 69.08 | 77.92 | 160 | 133 | 94.80 |
| Net profit margin | +1.6% | +4.9% | +3.9% | +3.9% | +8.3% | +7.7% | +6.3% |
| EPS (βΉ) | (3.94) | 7.36 | 5.63 | 6.36 | 13.02 | 10.80 | 6.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.70 | 24.70 | 24.70 | 24.66 | 24.66 | 24.66 | 24.66 |
| Reserves & surplus | 1,174 | 1,238 | 1,163 | 1,109 | 1,043 | 909 | 792 |
| Shareholders' funds (net worth) | 1,199 | 1,262 | 1,188 | 1,133 | 1,068 | 933 | 817 |
| Secured loans | 552 | 630 | 712 | 663 | 559 | 514 | 551 |
| Unsecured loans | 132 | 134 | 106 | 84.99 | 116 | 95.94 | 94.92 |
| Total debt | 684 | 765 | 818 | 748 | 675 | 610 | 646 |
| Total liabilities | 1,990 | 2,102 | 2,092 | 1,950 | 1,796 | 1,566 | 1,481 |
| Assets | |||||||
| Gross block | 2,404 | 2,225 | 1,802 | 1,564 | 1,388 | 1,128 | 1,065 |
| Net block | 1,333 | 1,364 | 1,071 | 948 | 879 | 713 | 735 |
| Capital work in progress | 94.50 | 121 | 414 | 412 | 295 | 254 | 161 |
| Investments | 9.50 | 9.50 | 5.40 | 5.31 | 10.92 | 0.62 | 0.69 |
| Inventories | 358 | 334 | 304 | 317 | 329 | 267 | 312 |
| Sundry debtors | 442 | 522 | 550 | 442 | 438 | 486 | 340 |
| Cash & bank balances | 13.80 | 17.90 | 20.80 | 59.53 | 49.09 | 36.81 | 63.57 |
| Loans & advances | 70.60 | 122 | 91.70 | 121 | 138 | 89.56 | 58.29 |
| Total current assets | 884 | 997 | 966 | 939 | 954 | 879 | 775 |
| Total current liabilities | 371 | 395 | 364 | 403 | 381 | 310 | 255 |
| Net working capital | 513 | 602 | 602 | 536 | 573 | 569 | 520 |
| Total assets | 1,990 | 2,102 | 2,092 | 1,950 | 1,796 | 1,566 | 1,481 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 12.90 | 12.60 | 26.70 | 11.44 | 7.64 | 31.68 | 11.41 |
| Net cash from operating activities | 302 | 280 | 187 | 315 | 294 | 229 | 285 |
| Net cash from investing activities | (145) | (136) | (174) | (292) | (284) | (156) | (164) |
| Net cash from financing activities | (160) | (144) | (27.00) | (7.68) | (5.56) | (96.87) | (101) |
| Net change in cash | (3.30) | 0.30 | (14.10) | 15.27 | 3.80 | (24.05) | 20.27 |
| Closing cash | 13.80 | 17.90 | 20.80 | 59.53 | 49.09 | 36.81 | 63.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -7.9% | +4.2% | -11.8% | +4.1% | +12.9% | +14.1% | - |
| EBITDA growth | -58.8% | +23.1% | +3.8% | -24.5% | +5.5% | +25.3% | - |
| PBT growth | - | +29.9% | -9.5% | -51.8% | +5.9% | +63.1% | -15.1% |
| Net income growth | -69.8% | +30.7% | -11.3% | -51.4% | +20.5% | +40.4% | - |
| Revenue CAGR (3Y) | -5.4% | -1.4% | +1.2% | +10.3% | +6.9% | +9.9% | +14.1% |
| EBITDA CAGR (3Y) | -19.2% | -1.2% | -6.2% | -0.1% | +4.5% | +10.1% | +9.3% |
| Profitability & leverage | |||||||
| Net income margin | -2.8% | +4.9% | +3.9% | +3.9% | +8.3% | +7.7% | +5.6% |
| Return on capital employed | +3.4% | +9.5% | +7.5% | +8.2% | +14.9% | +15.9% | +13.4% |
| Return on net worth | +2.2% | +7.4% | +6.0% | +7.1% | +16.0% | +15.2% | +12.1% |
| Debt / equity | 0.59 | 0.65 | 0.67 | 0.65 | 0.64 | 0.72 | 0.83 |
| Long-term debt / equity | 0.30 | 0.32 | 0.39 | 0.35 | 0.27 | 0.32 | 0.38 |
| Interest cover | -218.66 | 38.74 | 37.78 | 32.49 | 12.75 | 15.23 | 29.90 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.74 | 0.92 | 1.06 | 1.37 | 1.54 | 1.57 | 1.49 |
| Inventory turnover | 4.95 | 5.83 | 5.75 | 6.27 | 6.52 | 5.94 | 4.45 |
| Debtors turnover | 3.55 | 3.47 | 3.60 | 4.60 | 4.21 | 4.17 | 4.37 |
| EPS (βΉ) | (3.94) | 7.36 | 5.63 | 6.36 | 13.02 | 10.80 | 6.85 |
| Dividend per share (βΉ) | 0.60 | 1.40 | 1.20 | 1.20 | 1.60 | 2.00 | 1.20 |
| Book value per share (βΉ) | 97.09 | 102.20 | 96.16 | 91.93 | 86.62 | 75.70 | 66.22 |
Timeline of Hikal
4 dated milestones of Hikal across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Hikal is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $9.1M.
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Hikal
Hikal has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed competitors of Hikal
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hikal
The website of Hikal (hikal.com) receives about 10.3K visits a month.
- Monthly visits10.3K
▼ 5.8% vs previous month
Websites whose visitors overlap most with Hikal. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
valsynthese.ch | valsynthese.ch | 100% | β | ||
| kalyanisteels.com | 73% | 8.1K | #1,716,744 | View details | |
| bharatforge.com | 73% | 27.5K | #733,394 | View details | |
| panchsheelorganics.com | 29% | 21.5K | #1,592,649 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Hikal (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hikal
Complete news archive for Hikal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hikal
Hikal was founded in 1988 and raised its 1st funding round 20 years after it was founded.
Hikal is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Hikal has 2,645 employees.
The primary company behind Hikal, Hikal Limited, reported revenue of βΉ1,725 Cr for FY 2026, down 8% year on year.
Hikal was founded in 1988 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical and chemical sectors, where contract research, custom synthesis, and manufacturing of active pharmaceutical ingredients (APIs) and intermediates are conducted. Services extend to supplying ingredients for medicine production and providing research and development support for life sciences and biotechnology firms developing new products.
Hikal's top competitors include Laurus Labs, Symbiotec and SeQuent.
Hikal offers Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products.
Yes, Hikal is publicly traded on NSE under the ticker symbol HIKAL.
Hikal has 1 investor. Key investors include International Finance Corporation.
Hikal is associated with 2 legal entities: Hikal Limited, Hikal Pharmaceuticals Limited.
The legal entities of Hikal currently have 14 directors, including Shivani Bhasin Sachdeva, Sameer Jai Hiremath, Amit Babasaheb Kalyani and others.
